Cargando…

Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection

The introduction of the direct-acting antivirals (DAA) has substantially improved the effectiveness of the therapy in patients with chronic hepatitis C. We aimed to compare the efficacy of pangenotypic and genotype-specific DAA in the cohort of genotype (GT) four patients with HCV monoinfection and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zarębska-Michaluk, Dorota, Jaroszewicz, Jerzy, Parfieniuk-Kowerda, Anna, Pawłowska, Małgorzata, Janczewska, Ewa, Berak, Hanna, Janocha-Litwin, Justyna, Klapaczyński, Jakub, Tomasiewicz, Krzysztof, Piekarska, Anna, Krygier, Rafał, Citko, Jolanta, Tronina, Olga, Dobrowolska, Krystyna, Flisiak, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781964/ https://www.ncbi.nlm.nih.gov/pubmed/35054088 http://dx.doi.org/10.3390/jcm11020389

Ejemplares similares

Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2021)

Pangenotypic triple versus double therapy in HCV-infected patients after prior failure of direct-acting antivirals
por: Flisiak, Robert, et al.
Publicado: (2023)

Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens
por: Tronina, Olga, et al.
Publicado: (2023)

HCV Genotype Has No Influence on the Incidence of Diabetes—EpiTer Multicentre Study
por: Rajewski, Paweł, et al.
Publicado: (2022)

Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2023
por: Tomasiewicz, Krzysztof, et al.
Publicado: (2023)

Five-Year Follow-Up of Cured HCV Patients under Real-World Interferon-Free Therapy
por: Flisiak, Robert, et al.
Publicado: (2021)

Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Prevalence of HCV genotypes in Poland – the EpiTer study
por: Flisiak, Robert, et al.
Publicado: (2016)

645 Structural Bone Deficits in HIV/HCV, HCV-Monoinfected, and HIV-Monoinfected Women
por: Lo Re, Vincent, et al.
Publicado: (2014)

Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders
por: Dybowska, Dorota, et al.
Publicado: (2023)

Prevalence and Risk Factors of HCV/HIV Co-Infection and HCV Genotype Distribution in North-Eastern Poland
por: Grzeszczuk, Anna, et al.
Publicado: (2015)

Perspectives of hepatitis C virus (HCV) elimination in Poland
por: Flisiak, Robert, et al.
Publicado: (2019)

Liver Enzyme Alterations in HCV-Monoinfected and HCV/HIV-Coinfected Patients
por: Langohr, Klaus, et al.
Publicado: (2008)

Efficacy and safety of pegylated interferon α and ribavirin in patients monoinfected with HCV genotype 4
por: Kozielewicz, Dorota, et al.
Publicado: (2018)

Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients
por: Hatu, Giorgiana, et al.
Publicado: (2014)

Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders
por: de Gennaro, Nicolò, et al.
Publicado: (2020)

Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland
por: Pazgan-Simon, Monika, et al.
Publicado: (2023)

Pharmacologic management of HCV treatment in patients with HCV monoinfection vs. HIV/HCV coinfection: Does coinfection really matter?
por: Zuckerman, Autumn D., et al.
Publicado: (2019)

Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients
por: Maughan, A., et al.
Publicado: (2019)

Epidemiological features of patients infected with HCV genotype 4 in Poland: Epidemiology of HCV genotype 4 in Poland
por: Chlabicz, Slawomir, et al.
Publicado: (2011)

Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era
por: Brzdęk, Michał, et al.
Publicado: (2023)

The correlation of HCV RNA and HCV core antigen in different genotypes of HCV
por: Xiang, Yu, et al.
Publicado: (2018)

The occurrence of autoantibodies in patients with chronic HCV infection, including patients dialyzed and after kidney transplantation
por: Łapiński, Tadeusz W., et al.
Publicado: (2016)

Cellular Activation and Intracellular HCV Load in Peripheral Blood Monocytes Isolated from HCV Monoinfected and HIV-HCV Coinfected Patients
por: Dichamp, Isabelle, et al.
Publicado: (2014)

Global Elimination of HCV—Why Is Poland Still So Far from the Goal?
por: Tronina, Olga, et al.
Publicado: (2023)

HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes
por: Garbuglia, Anna Rosa, et al.
Publicado: (2014)

Molecular Epidemiology of HCV Monoinfection and HIV/HCV Coinfection in Injection Drug Users in Liuzhou, Southern China
por: Tan, Yi, et al.
Publicado: (2008)

Effects of Pegylated Interferon Alpha and Ribavirin (pegIFN-α/RBV) Therapeutic Approach on Regulatory T Cells in HCV-Monoinfected and HCV/HIV-Coinfected Patients
por: Grubczak, Kamil, et al.
Publicado: (2021)

Searching for the optimal population for hepatitis C virus screening in Poland
por: Piekarska, Anna, et al.
Publicado: (2020)

Performance of 6 HCV genotyping 9G test for HCV genotyping in clinical samples
por: Warkad, Shrikant Dasharath, et al.
Publicado: (2018)

Liver Fibrosis in HCV Monoinfected and HIV/HCV Coinfected Patients: Dysregulation of Matrix Metalloproteinases (MMPs) and Their Tissue Inhibitors TIMPs and Effect of HCV Protease Inhibitors
por: Latronico, Tiziana, et al.
Publicado: (2016)

Efficacy of HCV treatment in Poland at the turn of the interferon era – the EpiTer study
por: Flisiak, Robert, et al.
Publicado: (2016)

HCV monoinfection and HIV/HCV coinfection enhance T-cell immune senescence in injecting drug users early during infection
por: Grady, Bart P. X., et al.
Publicado: (2016)

Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2019)

Hepatitis C viral load in HCV-monoinfected and HCV/HIV-1-, HCV/HTLV-1/-2-, and HCV/HIV/HTLV-1/-2-co-infected patients from São Paulo, Brazil
por: Alves, Fabiana Aparecida, et al.
Publicado: (2018)

Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study
por: Tronina, Olga, et al.
Publicado: (2021)

Differences in outpatient care and treatment utilization for patients with HIV/HCV coinfection, HIV, and HCV monoinfection, a cross-sectional study
por: Johnson, Terence L, et al.
Publicado: (2014)

Longitudinal Assessment of Multiple Immunological and Inflammatory Parameters during Successful DAA Therapy in HCV Monoinfected and HIV/HCV Coinfected Subjects
por: Zuccalà, Paola, et al.
Publicado: (2022)

Deconvoluting the Composition of Low-Frequency Hepatitis C Viral Quasispecies: Comparison of Genotypes and NS3 Resistance-Associated Variants between HCV/HIV Coinfected Hemophiliacs and HCV Monoinfected Patients in Japan
por: Ogishi, Masato, et al.
Publicado: (2015)

HCV genotypes distribution pattern in India
por: Bokharaei-Salim, Farah, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_386tu5976rc5ia31ebrvbqi94a